<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "https://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">Vestnik dermatologii i venerologii</journal-id><journal-title-group><journal-title xml:lang="en">Vestnik dermatologii i venerologii</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник дерматологии и венерологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0042-4609</issn><issn publication-format="electronic">2313-6294</issn><publisher><publisher-name xml:lang="en">Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">16998</article-id><article-id pub-id-type="doi">10.25208/vdv16998</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL STUDIES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>НАУЧНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Unknown</subject></subj-group></article-categories><title-group><article-title xml:lang="en">PERSONALIZED MULTISPECTRAL PHOTODYNAMIC THERAPY FOR THE TREATMENT OF MILD-TO-MODERATE ACNE VULGARIS: RESULTS OF A PROSPECTIVE SINGLE-ARM PILOT STUDY</article-title><trans-title-group xml:lang="ru"><trans-title>ПЕРСОНАЛИЗИРОВАННАЯ МУЛЬТИСПЕКТРАЛЬНАЯ ФОТОДИНАМИЧЕСКАЯ ТЕРАПИЯ В ЛЕЧЕНИИ ВУЛЬГАРНЫХ АКНЕ ЛЁГКОЙ И СРЕДНЕЙ СТЕПЕНИ ТЯЖЕСТИ: РЕЗУЛЬТАТЫ ПРОСПЕКТИВНОГО ОДНОГРУППОВОГО ПИЛОТНОГО ИССЛЕДОВАНИЯ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0795-8567</contrib-id><name-alternatives><name xml:lang="en"><surname>Akulinina</surname><given-names>Iuliia K.</given-names></name><name xml:lang="ru"><surname>Акулинина</surname><given-names>Юлия Константиновна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>к.м.н., доцент</p></bio><email>AkulininaJuK@rmapo.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-0997-0630</contrib-id><name-alternatives><name xml:lang="en"><surname>Sarycheva</surname><given-names>Viktoriia S.</given-names></name><name xml:lang="ru"><surname>Сарычева</surname><given-names>Виктория Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>ординатор 2 года и лаборант кафедры дерматовенерологии и косметологии РМАНПО</p></bio><email>sarychevavs@rmapo.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-3064-3634</contrib-id><name-alternatives><name xml:lang="en"><surname>Markova</surname><given-names>Tatyana S.</given-names></name><name xml:lang="ru"><surname>Маркова</surname><given-names>Татьяна Сергеевна</given-names></name></name-alternatives><bio xml:lang="ru"><p>Врач-дерматолог, косметолог</p></bio><email>dr.markovats@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0009-6209-3058</contrib-id><name-alternatives><name xml:lang="en"><surname>Abramov</surname><given-names>Egor A.</given-names></name><name xml:lang="ru"><surname>Абрамов</surname><given-names>Егор Андреевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>Пластический хирург, косметолог</p></bio><email>dr.abramov@bk.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1450-4942</contrib-id><contrib-id contrib-id-type="spin">6708-7386</contrib-id><name-alternatives><name xml:lang="en"><surname>Bakulev</surname><given-names>Andrey L.</given-names></name><name xml:lang="ru"><surname>Бакулев</surname><given-names>Андрей Леонидович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д.м.н., профессор</p></bio><email>al_ba05@mail.ru</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff id="aff1"><institution>ФГБОУ ДПО РМАНПО Минздрава России</institution></aff><aff id="aff2"><institution>Клиника косметологии доктора Абрамова, г. Екатеринбург</institution></aff><aff-alternatives id="aff3"><aff><institution xml:lang="en">Central State Medical Academy, Department of Presidential Affairs</institution></aff><aff><institution xml:lang="ru">Центральная государственная медицинская академия Управления делами Президента РФ</institution></aff></aff-alternatives><content-language>ru</content-language><pub-date date-type="preprint" publication-format="electronic" iso-8601-date="2026-09-28"><day>28</day><month>09</month><year>2026</year></pub-date><volume>102</volume><issue>4</issue><issue-title xml:lang="ru"/><history><date date-type="received" iso-8601-date="2026-04-27"><day>27</day><month>04</month><year>2026</year></date><date date-type="accepted" iso-8601-date="2026-08-26"><day>26</day><month>08</month><year>2026</year></date></history><pub-history><event event-type="received"><event-desc>Received:<date date-type="received" iso-8601-date="2026-04-27"><day>27</day><month>04</month><year>2026</year></date></event-desc></event><event event-type="accepted"><event-desc>Accepted:<date date-type="accepted" iso-8601-date="2026-08-26"><day>26</day><month>08</month><year>2026</year></date></event-desc></event></pub-history><permissions><copyright-statement xml:lang="en">Copyright ©; , Akulinina I.K., Sarycheva V.S., Markova T.S., Abramov E.A., Bakulev A.L.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; , Акулинина Ю.К., Сарычева В.С., Маркова Т.С., Абрамов Е.А., Бакулев А.Л.</copyright-statement><copyright-holder xml:lang="en">Akulinina I.K., Sarycheva V.S., Markova T.S., Abramov E.A., Bakulev A.L.</copyright-holder><copyright-holder xml:lang="ru">Акулинина Ю.К., Сарычева В.С., Маркова Т.С., Абрамов Е.А., Бакулев А.Л.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://vestnikdv.ru/jour/article/view/16998">https://vestnikdv.ru/jour/article/view/16998</self-uri><abstract xml:lang="en"><p>Acne vulgaris affects up to 85% of individuals aged 12–24 years, highlighting the need for effective and safe therapeutic approaches. Photodynamic therapy (PDT) using a combined photosensitizer based on 5-aminolevulinic acid 0.5% and chlorin e6 0.5% (5-ALA+Ce6) represents a promising treatment strategy.</p> <p><bold>Objective:</bold> To evaluate the efficacy and safety of multispectral PDT using the REVIXAN LED system in patients with mild to moderate acne.</p> <p><bold>Methods:</bold> The study included 10 female patients aged 17–25 years (mean 20.9±2.6) without hyperandrogenism. Patients received 2–3 PDT sessions (400, 633, 660, 850 nm) at 1-week intervals. Photosensitizer exposure time was 20–40 minutes, followed by 20 minutes of light exposure. Efficacy was assessed using the Global Acne Grading System (GAGS), Dermatological Acne Index (DAI), FotoFinder imaging (inflammatory lesion count), corneometry, and sebumetry. Statistical analysis was performed using a paired Student’s t-test.</p> <p><bold>Results:</bold> A 45% reduction in inflammatory lesions, 40% decrease in sebum levels, and 50% reduction in GAGS score were observed (p&lt;0.001). Skin hydration significantly increased (p&lt;0.01). Adverse events (erythema, burning sensation) were mild and transient.</p> <p><bold>Conclusion:</bold> Multispectral PDT with the REVIXAN system and 5-ALA+Ce6 demonstrates high efficacy and a favorable safety profile in the treatment of mild to moderate acne.</p> <p><bold>Keywords:</bold> acne vulgaris, photodynamic therapy, 5-aminolevulinic acid, chlorin e6, photobiomodulation.</p></abstract><trans-abstract xml:lang="ru"><p>Акне вульгарное поражает до 85% лиц 12–24 лет, что обуславливает актуальность поиска эффективных и безопасных методов терапии. Перспективным подходом является фотодинамическая терапия (ФДТ) с комбинированным фотосенсибилизатором на основе 5-аминолевулиновой кислоты 0,5% и хлорина е6 0,5% (5-АЛК+Се6).</p> <p><bold>Цель:</bold> оценить эффективность и безопасность мультиспектральной ФДТ с LED-системой REVIXAN у пациенток с акне лёгкой и средней степени.</p> <p><bold>Методы:</bold> в исследование включены 10 пациенток 17–25 лет (M=20,9±2,6) без гиперандрогении. Проведено 2–3 сеанса ФДТ (400, 633, 660, 850 нм) с интервалом 1 неделя. Экспозиция ФС — 20–40 мин, световая — 20 мин. Оценка: GAGS, ДИА, FotoFinder, себуметрия, корнеометрия. Статистика — парный t-критерий.</p> <p><bold>Результаты:</bold> снижение воспалительных элементов на 45%, себума — на 40%, GAGS — на 50% (p&lt;0,001). Увлажнённость кожи увеличилась (p&lt;0,01). Побочные эффекты (эритема, жжение) были лёгкими и кратковременными.</p> <p><bold>Заключение:</bold> мультиспектральная ФДТ с REVIXAN и 5-АЛК+Се6 эффективна и безопасна при акне лёгкой и средней степени.</p> <p><bold>Ключевые слова:</bold> акне, ФДТ, 5-АЛК, хлорин Е6, фотобиомодуляция.</p></trans-abstract><funding-group/></article-meta></front><body></body><back><ref-list/></back></article>
